AvenCell Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
58
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$36M
- Investors
-
12
AvenCell General Information
Description
Developer of T cell-based immunotherapies intended to support cancer treatment. The company focuses on building chimeric antigen receptor T cells for precise targeting of cancer antigens to overcome the limitations of current-generation CAR-T cell therapies with an improved therapeutic window and substantially expand the types of cancer treatable with adoptive cell therapy, including solid tumors, enabling clinical researchers to create a pipeline of autologous and allogeneic universal reprogrammable T cell products, focused initially on hard-to-treat cancers.
Contact Information
Website
www.avencell.comCorporate Office
- 500 Forge Road
- Suite 302
- Watertown, MA 02472
- United States
Corporate Office
- 500 Forge Road
- Suite 302
- Watertown, MA 02472
- United States
AvenCell Timeline
AvenCell Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series C) | 17-Sep-2026 | $36M | Completed | Clinical Trials - Phase 2 | ||
| 4. Early Stage VC | 11-Sep-2025 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series B) | 18-Oct-2024 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A) | $65.8M | $65.8M | Completed | Pre-Clinical Trials | ||
| 1. Joint Venture | 30-Jul-2021 | Completed | Pre-Clinical Trials |
AvenCell Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A-2a | 13,326,226 | $0.000100 | 8% | $1.65 | $1.65 | $1.65 | 9.66% | |
| Series A-1 | 26,652,452 | $0.000100 | 8% | $1.65 | $1.65 | $1.65 | 19.33% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
AvenCell Signals
AvenCell Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| JIC Venture Growth Investments | Venture Capital | Minority | ||
| Ligand Pharmaceuticals | Corporation | Minority | ||
| Therapy Acceleration Program (TAP) | Not-For-Profit Venture Capital | Minority | ||
| JVC Investment Partners | Family Office | Minority | ||
| Eight Roads | Corporate Venture Capital | Minority |
AvenCell FAQs
-
When was AvenCell founded?
AvenCell was founded in 2021.
-
Where is AvenCell headquartered?
AvenCell is headquartered in Watertown, MA.
-
What is the size of AvenCell?
AvenCell has 58 total employees.
-
What industry is AvenCell in?
AvenCell’s primary industry is Drug Discovery.
-
Is AvenCell a private or public company?
AvenCell is a Private company.
-
What is AvenCell’s current revenue?
The current revenue for AvenCell is .
-
How much funding has AvenCell raised over time?
AvenCell has raised $228M.
-
Who are AvenCell’s investors?
JIC Venture Growth Investments, Ligand Pharmaceuticals, Therapy Acceleration Program (TAP), JVC Investment Partners, and Eight Roads are 5 of 12 investors who have invested in AvenCell.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process